Transcription factor 7-like 2 polymorphism and colon cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 4, 2008, Pages 978-982

  Slattery, Martha L ^a   Folsom, Aaron R ^b   Wolff, Roger ^a   Herrick, Jenifer ^a   Caan, Bette J ^b   Potter, John D ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; GENOMIC DNA; NONSTEROID ANTIINFLAMMATORY AGENT; TRANSCRIPTION FACTOR 7 LIKE 2;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA EXTRACTION; DRUG USE; FEMALE; GENE; GENE INTERACTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK REDUCTION; TRANSCRIPTION FACTOR 7 LIKE 2 GENE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; POLYMORPHISM, GENETIC; TCF TRANSCRIPTION FACTORS;

EID: 42149181801     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2687     Document Type: Article

References (28)

1. Salonen JT, Uimari P, Aalto JM, et al. Type 2 diabetes whole-genome association study in four populations: the DiaGen consortium. Am J Hum Genet 2007;81:338-45.
2. Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007;117:2155-63.
3. Prunier C, Hocevar BA, Howe PH. Wnt signaling: physiology and pathology. Growth Factors 2004;22:141-50.
4. Wong NA, Pignatelli M. β-Catenin - a linchpin in colorectal carcinogenesis? Am J Pathol 2002;160:389-401.
5. Samowitz WS, Slattery ML, Sweeney C, Herrick J, Wolff RK, Albertsen H. APC mutations and other genetic and epigenetic changes in colon cancer. Mol Cancer Res 2007;5:165-70.
6. Domenyuk VP, Litovkin KV, Verbitskaya TG, Dubinina VG, Bubnov VV. Identification of new DNA markers of endometrial cancer in patients from the Ukrainian population. Exp Oncol 2007;29:85-93.
7. Burwinkel B, Shanmugam KS, Hemminki K, et al. Transcription factor 7-like 2 (TCF7L2) variant is associated with familial breast cancer risk: a case-control study. BMC Cancer 2006;6:268.
8. Schneikert J, Behrens J. The canonical Wnt signalling pathway and its APC partner in colon cancer development. Gut 2007;56:417-25.
9. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 2001;293:1673-7.
10. Slattery ML, Edwards S, Curtin K, et al. Physical activity and colorectal cancer. Am J Epidemiol 2003;158:214-24.
11. Slattery ML, Potter J, Caan B, et al. Energy balance and colon cancer - beyond physical activity. Cancer Res 1997;57:75-80.
12. Edwards S, Slattery ML, Mori M, et al. Objective system for interviewer performance evaluation for use in epidemiologic studies. Am J Epidemiol 1994;140:1020-8.
13. Slattery ML, Caan BJ, Duncan D, Berry TD, Coates A, Kerber R. A computerized diet history questionnaire for epidemiologic studies. J Am Diet Assoc 1994;94:761-6.
14. Slattery ML, Samowitz W, Curtin K, et al. Associations among IRS1, IRS2, IGF1, and IGFBP3 genetic polymorphisms and colorectal cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1206-14.
15. Slattery ML, Curtin K, Anderson K, et al. Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst 2000;92:1831-6.
16. Camp NJ, Slattery ML. Classification tree analysis: a statistical tool to investigate risk factor interactions with an example for colon cancer (United States). Cancer Causes Control 2002;13:813-23.
17. Slattery ML, Samowitz W, Hoffman M, Ma KN, Levin TR, Neuhausen S. Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev 2004;13:538-45.
18. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992;52:5575-89.
19. Sandler RS. Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer. Important Adv Oncol 1996;123-37.
20. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002;109:1321-6.
21. Fang V, Foye WO, Robinson SM, Jenkins HJ. Hypoglycemic activity and chemical structure of the salicylates. J Pharm Sci 1968;57:2111-6.
22. Graef I, Gibbons DM. Salicylates and carbohydrate metabolism. Diabetes 1960;9:416-8.
23. Powell ED, Field RA. Studies on salicylates and complement in diabetes. Diabetes 1966;15:730-3.
24. McRae JR, Chen M, Robertson RP. Improvement of defective insulin responses to glucose, arginine, and β-adrenergic stimulation in diabetics by sodium salicylate. Adv Prostaglandin Thromboxane Res 1980;8:1287-9.
25. 1Baron SH. Salicylates as hypoglycemic agents. Diabetes Care 1982;5:64-71.
26. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001;131:3109-20S.
27. Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007;316:1341-5.
28. Wang J, Kuusisto J, Vanttinen M, et al. Variants of transcription factor 7-like 2 (TCF7L2) gene predict conversion to type 2 diabetes in the Finnish Diabetes Prevention Study and are associated with impaired glucose regulation and impaired insulin secretion. Diabetologia 2007;50:1192-200.